New gene shown to cause Parkinson’s disease
Source: Northwestern University
Northwestern Medicine scientists have discovered a new cause of Parkinson’s disease: mutations in a gene called TMEM230. This appears to be the third gene definitively linked to confirmed cases of the common movement disorder.
Scientists provided evidence of TMEM230 mutations in patients with Parkinson’s disease from both North America and Asia. They also demonstrated that the gene is responsible for producing a protein involved in packaging the neurotransmitter dopamine in neurons. Loss of dopamine-producing neurons is a defining characteristic of Parkinson’s disease.
Taken together, the study’s findings provide new clues to explain how Parkinson’s disease develops in the brain. Those clues may inform future therapies for the disorder, which currently has no cure and few known causes.
“Previous research has associated Parkinson’s disease with various factors in the environment, but the only direct causes that are known are genetic,” said principal investigator Teepu Siddique, M.D., the Les Turner ALS Foundation/Herbert C. Wenske Foundation Professor at Northwestern University Feinberg School of Medicine. “Many genes have been claimed to cause Parkinson’s disease, but they haven’t been validated. We show that mutations in this new gene lead to pathologically and clinically proven cases of the disease.”
About 15 percent of Parkinson’s disease cases are thought to be caused by genetics, such as mutations in two genes called SNCA and LRRK2. Siddique said that other genes have only been associated with features of parkinsonism, a general term for neurological disorders with motor symptoms.
The Northwestern Medicine team’s proof that mutations in TMEM230 lead to Parkinson’s disease is the result of 20 years of research conducted with collaborators around the world.
The project began in 1996, when Siddique and study first author Han-Xiang Deng, M.D., Ph.D., began investigating a family with members who had typical symptoms of Parkinson’s disease. Using DNA samples provided by co-author Ali Rajput, M.D., from the University of Saskatchewan, Siddique and Deng performed genome-wide analysis on 65 of the family’s members, including 13 with the disease, in hopes of finding a common mutation that could explain the prevalence.
They were able to narrow the search down to a small region of DNA on chromosome 20 that contained 141 known genes. Using whole exome sequencing technology, they then compared DNA variations — genetic differences — in one healthy family member to those in four family members with the disease. The scientists found more than 90,000 variants before eventually identifying TMEM230 as the gene with disease-causing mutation.
“This was a totally new gene. We didn’t know its function,” Deng explained. “So we did a series of studies to find out where the protein encoded by this gene is located and what it does.”
The scientists discovered that TMEM230 encodes a protein that extends across the membrane of tiny sacks inside neurons called synaptic vesicles, which store neurotransmitters before they’re released from one cell to another.
“Current symptomatic treatments for Parkinson’s disease increase the neurotransmitter dopamine that is released by these synaptic vesicles to cells that project into different parts of the brain controlling motor activity, mood and many other organ systems affected by the disease,” Siddique said.
The scientists hypothesize that the protein is involved in the movement of these vesicles.
“We believe that vesicle trafficking defects are a key mechanism of Parkinson’s disease, not just for cases with this mutation, but a common pathway for the majority of cases. All three of the authenticated genes are concentrated on synaptic vesicles,” Deng said. “Our new findings suggest that normalizing synaptic vesicle trafficking may be a strategy for future therapeutic development. We can develop drugs to promote this critical pathway.”
(A Wellness Update is a magazine devoted to up-to-the minute information on health issues from physicians, major hospitals and clinics, universities and health care agencies across the U.S. Online at www.awellnessupdate.com.)
(c) 2016 www.awellnessupdate.COM. DISTRIBUTED BY TRIBUNE CONTENT AGENCY, LLC.
By Eleanor Laise, Kiplinger Retirement Report When an older adult racks up unpaid long-term-care bills, who's
Mayo Clinic Q&A DEAR MAYO CLINIC: I was recently diagnosed with vascular Ehlers-Danlos syndrome. My doctor
Mayo Clinic Q&A DEAR MAYO CLINIC: Should all postmenopausal women take calcium supplements to prevent osteoporosis,
By Sandra Block, Kiplinger Personal Finance How stressed-out are we? Consider this: In some cities, "rage
By Cleveland Clinic's Chronic Conditions Team In the past, if you had minor surgery or an